RepliCel Life Sciences has been granted a patent for an innovative injection device that delivers liquid substances, including cells, into tissue. The device features a cartridge, injector with a needle, and a delivery mechanism for precise injections. The system can be connected to a control unit for a dermal injection system. GlobalData’s report on RepliCel Life Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights RepliCel Life Sciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on RepliCel Life Sciences, Remote infusion monitoring was a key innovation area identified from patents. RepliCel Life Sciences's grant share as of February 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.

Injection device for delivering liquid substance into tissue

Source: United States Patent and Trademark Office (USPTO). Credit: RepliCel Life Sciences Inc

A recently granted patent (Publication Number: US11865324B2) discloses a method for delivering a liquid substance, such as cells or hyaluronic acid, into tissue using an injection device. The injection device includes an injector with at least one needle, a cartridge with a chamber for holding the liquid substance, and a plunger to change the chamber's volume. A delivery mechanism independently moves the plunger and needle towards the tissue, allowing for precise control over the injection process. The device's electromechanical drive device advances and retracts the needle while adjusting the cartridge volume, enabling the liquid substance to be injected into the body even while the needle is being retracted. This innovative method offers a more controlled and efficient way of delivering liquid substances into tissue, potentially improving treatment outcomes.

The patent outlines a specific application of the method for delivering hyaluronic acid into tissue, highlighting the versatility of the injection device for various types of liquid substances. By utilizing the unique features of the injection device, including the independent movement of the plunger and needle, healthcare professionals can ensure accurate and targeted delivery of hyaluronic acid or other substances into the body. The device's design, with a movable distal drive and stationary proximal drive connected by a threaded rod, allows for precise control over the injection process, enhancing the overall effectiveness of the treatment. This patented method represents a significant advancement in the field of tissue injection technology, offering healthcare providers a more efficient and reliable way to deliver liquid substances for therapeutic purposes.

To know more about GlobalData’s detailed insights on RepliCel Life Sciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies